Highest-materiality recent filing
Intelligent Bio Solutions completes final clinical study; FDA 510(k) submission on track for H2 2026
Completed multi-site Method Comparison Study; all clinical data collection for FDA 510(k) program now complete.
Study confirms system can be effectively administered by operators with no specialist background.
Completed independent third-party penetration testing; all cybersecurity review items resolved.
Precision testing included over 1,600 tests across three production runs and three independent sites.
Interference Study with 75 healthy adults to validate the system's codeine specificity against everyday substances.
Intelligent Bio Q3 revenue $1.06M (+46% YoY); cartridge sales up 59%
Q3 cartridge revenue $703,538, up 59% YoY, representing 66% of total sales.
Intelligent Bio grants restricted shares to CEO/CFO/directors; updates ATM facility
CEO Harry Simeonidis and CFO Spiro Sakiris each receive 9,150 time-vesting and 21,350 performance-vesting restricted shares.
First Intelligent Fingerprinting Drug Screening Readers manufactured by Syrma Johari MedTech deployed to U.K. and Europe customers.
Intelligent Bio Solutions Q2 revenue $896,774, up 48% YoY; reader sales surge 104%
Q2 total revenue $896,774, up 48% YoY; reader sales $246,519 (+104%), cartridge sales $516,754 (+33%).
Intelligent Bio sees 48% Q2 revenue growth YoY, H1 revenue tops $2M
Fiscal Q2 2026 revenue expected up ~48% YoY; readers more than double (+104% YoY).
Partnered with Cliantha Research for a study in 40 adults to establish codeine detection cut-off levels.
Intelligent Bio Solutions closes $10M private placement; funds FDA submission and expansion
Gross proceeds of ~$10M from sale of 2,298,850 units at $4.35/unit (common/pre-funded warrant + two Series K warrants).
Partnership with Syrma Johari Medtech to scale production of fingerprint drug screening reader; expects annual production cost savings >40%.
Nasdaq deficiency letter for bid price non-compliance; 1-for-10 reverse stock split effected
Received Nasdaq deficiency letter on Dec 15 for closing bid price below $1 for 30 consecutive business days.
Revenue $1.11M (+28% YoY, +32% sequential); cartridge sales 57.6% of total revenue.
Intelligent Bio Solutions reports preliminary Q1 FY2026 revenue over $1M, up ~32% sequentially
Preliminary revenue >$1M for fiscal Q1 ended Sep 30, 2025; third consecutive quarter of growth.
INBS adds 33 new customer accounts in Q1 FY2026, up 50% YoY; total active accounts exceed 480
Added 33 new customer accounts in fiscal Q1 ended Sept 30, 2025, a 50% increase YoY.
Elected four directors: Boyages, Hurd, Isenberg, Fraser. Boyages received 1,349,921 for, 503,182 withheld.
Intelligent Bio Solutions must resubmit FDA 510(k) for drug screening system after new info request
FDA requested new additional information in a letter dated September 12, 2025, requiring a new 510(k) resubmission.
Preliminary Q4 FY2025 revenue growth of ~16% sequentially and year-over-year, driven by higher-margin cartridge sales and account growth.
Intelligent Bio Solutions raises $3.8M via warrant exercise inducement, funds FDA 510k filing
Gross proceeds of ~$3.8M from exercise of existing Series G and H-1 warrants at $1.90/share; closing July 28, 2025.
INBS strengthens FDA 510(k) with new fingerprint sweat detection data
Cybersecurity penetration and EMC testing completed to validate platform resilience.
Over 450 active accounts globally, with 35 new accounts added in fiscal Q3.
Intelligent Bio Solutions Q3 revenue $0.73M, up 20% QoQ; gross profit up 91% YoY
Revenue $0.73M in fiscal Q3, up 20% sequentially; nine-month revenue $2.21M, down 7% YoY.
Intelligent Bio Solutions expects sixth U.S. patent for fingerprint drug testing technology
Expected patent will protect lateral flow technology core to its drug screening system.
Gross proceeds $3.0M from 1.5M shares at $2.00 per share including full over-allotment exercise.
INBS Q2 FY2025 revenue falls 20% YoY; net loss widens to $2.26M; gross margin up 11pts
Revenue $607,494, down 20% YoY; net loss $2.25M vs $1.97M.
Preliminary Q2 FY2025 revenue ~$0.61M; 6-month revenue ~$1.48M; gross profit margin improved to 38.5% from 27.7%.
INBS preliminary Q2 revenue $0.61M; six-month gross profit up 32.6% to $0.57M, margin 38.5%
Unaudited revenue $0.61M for Q2, $1.48M for six months ended Dec 31, 2024.
On June 7, 2024, upon recommendation of the Nominating and Corporate Governance Committee, the Board appointed Nicola Fraser to the Board to fill the vacancy created by Mr. Tower’s resignation.
On June 6, 2024, Christopher Towers resigned from the Board of Directors (the “Board”) of Intelligent Bio Solutions Inc. (the “Company”), effective June 7, 2024.
On November 6, 2023, David Jenkins informed the Board of Directors (the “Board”) of Intelligent Bio Solutions Inc. (the “Company”) that he has decided to retire from service on the Board and will not stand for reelection to the Board at the Company’s annual meeting of stockholders for the fiscal year ended June 30, 2023 (the “2023 Annual Meeting”).
On June 9, 2023, Dr. George Margelis , a member of the Board of Directors (the “Board”) of Intelligent Bio Solutions Inc. (the Company”), and a member of the Audit Committee of the Board (the “Audit Committee”), resigned as a member of the Board effective as of such date.
Dr. Steven Boyages, who is stepping down as the Company’s Interim Chief Executive Officer.
elected Harry Simeonidis, who currently serves as the Company’s President Asia Pacific, Sales and Marketing, as the Company’s President and Chief Executive Officer, effective as of October 26, 2022.
each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.
each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.
On April 27, 2022, Leon Kempler, a member of the Board of Directors (the “Board”) of GBS Inc. (the “Company”), resigned as a member of the Board effective as of such date.
On March 19, 2022, Tom Parmakellis, a member of the Board of Directors (the “Board”) of GBS Inc. (the “Company”), resigned as a member of the Board effective as of such date.
On February 22, 2022, Prof. Jonathan Sessler, a member of the Board of Directors (the “Board”) of GBS Inc. (the Company”), resigned as a member of the Board effective as of such date.
Harry Simeonidis, who served as CEO and President of the Company, vacated these positions prior to Professor Boyages’ appointment as Interim CEO and was appointed to the position of President Asia Pacific, Sales and Marketing, effective October 29, 2021.
Max materiality 0.75 · Median 0.60 · Most common event other_material